Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 5/20 | 0.44 |
| ▸ | PGK1 | P00558 | 5/20 | 0.40 |
| ▸ | PGK2 | P07205 | 5/20 | 0.40 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3895848 | 0.98 | ENPP2 (0.43) | ENPP2PGK1PGK2DGAT2ALDH1A1 | |
| SCHEMBL8611486 | 0.80 | ALDH1A1 (0.43) | ALDH1A1GLATSHRL3MBTL1HPGD | |
| SCHEMBL2641797 | 0.72 | ALDH1A1 (0.52) | ENPP2PGK1PGK2DGAT2ALDH1A1 | |
| SCHEMBL145553 | 0.72 | ALDH1A1 (0.59) | ALDH1A1GLATSHRL3MBTL1HPGD | |
| SCHEMBL16353250 | 0.71 | PGK1 (0.50) | ENPP2PGK1PGK2DGAT2ALDH1A1 | |
| SCHEMBL1617420 | 0.71 | PGK1 (0.67) | ENPP2PGK1PGK2DGAT2SMN1; SMN2 | |
| SCHEMBL11374000 | 0.70 | HTR3E (0.43) | ALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL11309961 | 0.70 | ENPP2 (0.72) | ENPP2PGK1PGK2DGAT2ALDH1A1 | |
| SCHEMBL11304410 | 0.69 | ENPP2 (0.60) | ENPP2PGK1PGK2DGAT2ALDH1A1 | |
| SCHEMBL16353269 | 0.69 | PGK1 (0.49) | ENPP2PGK1PGK2ALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | claimed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | claimed |
| EP-0927217-B1 | ANGIOGENIC INHIBITORY COMPOUNDS | STARPHARMA PTY LTD (AU) | 2006-05-03 | — | — | EP | claimed |
| CN-1161128-C | Angiogenic inhibitory compounds | О | 2004-08-11 | — | — | CN | claimed |
| EP-1113805-A4 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LTD (AU) | 2004-05-19 | — | — | EP | claimed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | claimed |
| EP-1113806-A4 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LTD (AU) | 2003-06-25 | — | — | EP | claimed |
| EP-0927217-A4 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RES INST LTD (AU) | 2003-04-23 | — | — | EP | claimed |
| US-6464971-B1 | ANIONIC-CONTAINING MOIETY IS A NEURAMINIC- OR SIALIC ACID-CONTAINING. MOIETY, IT IS MODIFIED IN THE 4-POSITION BY SUBSTITUTION WITH AN AMINO, AMIDO, CYANO, AZIDO OR GUANIDO GROUP, OR IS UNSATURATED. | STARPHARMA LIMITED (AU) | 2002-10-15 | — | — | US | claimed |
| JP-2002524523-A | — | — | 2002-08-06 | — | — | JP | claimed |
| US-6426067-B1 | CARDIOVASCULAR DISORDERS; ANTITUMOR AGENTS | BIOMOLECULAR RESEARCH INSTITUTE, LTD. (AU) | 2002-07-30 | — | — | US | claimed |
| EP-1113805-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | claimed |
| EP-1113806-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | claimed |
| WO-2000015240-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | claimed |
| WO-2000015239-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | claimed |
| CN-1225654-A | Angiogenic inhibitory compounds | BIOMOLECULAR RES INST LTD (AU) | 1999-08-11 | — | — | CN | claimed |
| EP-0927217-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-07 | — | — | EP | claimed |
| WO-1998003573-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | ENPP2 357/4885PGK1 2543/4885PGK2 3069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.